Fig. 5: Clinical outcome of endometrioid ovarian carcinoma cases defined by combined HREP-based subtyping and TP53 mutation status. | npj Precision Oncology

Fig. 5: Clinical outcome of endometrioid ovarian carcinoma cases defined by combined HREP-based subtyping and TP53 mutation status.

From: Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification

Fig. 5: Clinical outcome of endometrioid ovarian carcinoma cases defined by combined HREP-based subtyping and TP53 mutation status.

a Disease-specific survival. Labelled hazard ratio (HR) represents comparison of PR-high with PR-low/TP53m group (P < 0.0001); additionally, HR for PR-high vs PR-low/TP53wt = 0.21, 95% CI 0.07–0.67 and HR for PR-low/TP53m vs PR-low/TP53wt = 2.56, 95% CI 1.14–5.75. b Progression-free survival. Labelled HR represents comparison of PR-high with PR-low/TP53m group (P < 0.0001); additionally, HR for PR-high vs PR-low/TP53wt = 0.34, 95% CI 0.13–0.92 and HR for PR-low/TP53m vs PR-low/TP53wt = 2.93, 95% CI 1.32–6.51. PR, progesterone receptor; m, mutant; wt, wild-type.

Back to article page